PaulL.MitchellMD

PubMed

• Evolving treatment paradigms in lung cancer: role of immuno-oncology.
  Mitchell P> ;Asia Pac J Clin Oncol. 2015-04-01
• Surgical resection and long-term survival outcome for non-small cell lung cancer: a comparison of Victorian population-based studies spanning a decade.
  Wright GM, Thursfield VJ, Ball DL, Richardson GE, Irving L, Giles GG, Mitchell P> ;Asia Pac J Clin Oncol. 2014-03-01
• NY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer (NSCLC).
  John T, Chen Y, Starmans MH, Walkiewicz M, Russell P, Azad A, Deb S, Altorki NK, Boutros PC, Mitchell P, Cebon JS> ;J. Clin. Oncol.. 2011-05-20
• Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.
  Do, H., Salemi, R., Murone, C., Mitchell, P.L., Dobrovic, A.> ;Cell Cycle. 2010 Nov 1
• High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer.
  Azad, A., Chionh, F., Scott, A.M., Lee, S.T., Berlangieri, S.U., White, S., Mitchell, P.L.> ;Mol Imaging Biol. 2010-08-01
• Staging 18FDG-PET in newly diagnosed small cell lung cancer (SCLC): 15-year institutional experience.
  Azad A, Chionh F, Scott A, White S, Mitchell PL> ;J. Clin. Oncol.. 2009-05-20
• Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models.
  Beltran PJ, Mitchell P, Moody G, Chung Y, Cajulis E, Belmontes B, Radinsky R, Calzone F> ;J. Clin. Oncol.. 2008-05-20
• Ten-year incidence of diabetes in older Australians: the Blue Mountains Eye Study.
  Cugati S, Wang JJ, Rochtchina E, Mitchell P> ;Med. J. Aust.. 2007-02-05
• Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
  Michael, M., Thompson, M., Hicks, R.J., Mitchell, P.L., Ellis, A., Milner, A.D., Di Iulio, J., Scott, A.M., Gurtler, V., Hoskins, J.M., Clarke, S.J., Tebbut, N.C., Foo...> ;J Clin Oncol. 2006 Sep 10
• Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
  Mitchell, P.L., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J.A., Clarke, S.> ;Clin Colorectal Cancer. 2006 Jul
• Impact of multiple impairments on quality of life, hospitalisations and use of aged-care services.
  Chia E, Wang JJ, Rochtchina E, Mitchell P> ;Med. J. Aust.. 2006-05-01
• Vision loss in Australia.
  Taylor HR, Keeffe JE, Vu HTV, Wang JJ, Rochtchina E, Pezzullo ML, Mitchell P> ;Med. J. Aust.. 2005-06-06
• Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer.
  Pavlakis N, Mitchell PL, Stynes G, Aristides M, Davey P, Rajan N, Arora B, Liepa AM> ;J. Clin. Oncol.. 2005-06-01
• Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC).
  Mitchell P, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, Clarke S, White S> ;J. Clin. Oncol.. 2005-06-01
• Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer.
  Rischin D, Burmeister B, Mitchell P, Boyer M, Macmanus M, Walpole E, Feigen M, Tin MM, Ball D> ;J. Clin. Oncol.. 2004-07-15
• "Smoking is a major cause of blindness".
  Mitchell P, Chapman S, Smith W> ;Med. J. Aust.. 1999-08-16
• KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
  Clarke K, Basser RL, Underhill C, Mitchell P, Bartlett J, Cher L, Findlay M, Dalley D, Pell M, Byrne M, Geldard H, Hill JS, Maher D, Fox RM, Green MD, Kaye AH> ;J. Clin. Oncol.. 1999-08-01
• Visual impairment in nursing home residents: the Blue Mountains Eye Study.
  Mitchell P, Hayes P, Wang JJ> ;Med. J. Aust.. 1997-01-20
• Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin.
  Harris DC, Simons LA, Mitchell P, Stewart JH> ;Med. J. Aust.. 1991-10-21
• Insomnia.
  Mitchell P, Mant A> ;Med. J. Aust.. 1991-02-04
• Anorexia nervosa presenting in a prepubertal boy.
  Hickie I, Mitchell P> ;Med. J. Aust.. 1989-02-06
• Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
  Jiang, X., Galettis, P., Links, M., Mitchell, P. L., McLachlan, A. J.> ;Br J Clin Pharmacol. 2008 Mar
• A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressiv...
  Mitchell, P. L., Marlton, P., Grigg, A., Seymour, J. F., Hertzberg, M., Enno, A., Herrmann, R., Bond, R., Arthur, C.> ;Leuk Lymphoma. 2008 May
• Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.
  Mitchell, P. L., Morland, B., Stevens, M. C., Dick, G., Easlea, D., Meyer, L. C., Pinkerton, C. R.> ;J Clin Oncol. 1997 Mar
• Granulocyte-macrophage-colony-stimulating factor in established febrile neutropenia.
  Mitchell, P. L., Pinkerton, C. R.> ;J Clin Oncol. 1999 Sep
• Join now to see all